321 related articles for article (PubMed ID: 28617150)
1. Atorvastatin-loaded nanostructured lipid carriers (NLCs): strategy to overcome oral delivery drawbacks.
Elmowafy M; Ibrahim HM; Ahmed MA; Shalaby K; Salama A; Hefesha H
Drug Deliv; 2017 Nov; 24(1):932-941. PubMed ID: 28617150
[TBL] [Abstract][Full Text] [Related]
2. Preparation, characterization, and
Saghafi Z; Mohammadi M; Mahboobian MM; Derakhshandeh K
Drug Dev Ind Pharm; 2021 Mar; 47(3):509-520. PubMed ID: 33650445
[TBL] [Abstract][Full Text] [Related]
3. Chlorogenic acid stabilized nanostructured lipid carriers (NLC) of atorvastatin: formulation, design and in vivo evaluation.
Khan S; Baboota S; Ali J; Narang RS; Narang JK
Drug Dev Ind Pharm; 2016; 42(2):209-20. PubMed ID: 26016780
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation.
Dudhipala N; Janga KY; Gorre T
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):616-625. PubMed ID: 29688077
[TBL] [Abstract][Full Text] [Related]
5. G5-PEG PAMAM dendrimer incorporating nanostructured lipid carriers enhance oral bioavailability and plasma lipid-lowering effect of probucol.
Qi R; Li YZ; Chen C; Cao YN; Yu MM; Xu L; He B; Jie X; Shen WW; Wang YN; van Dongen MA; Liu GQ; Banaszak Holl MM; Zhang Q; Ke X
J Control Release; 2015 Jul; 210():160-8. PubMed ID: 26003044
[TBL] [Abstract][Full Text] [Related]
6. Chitosan-coated nanostructured lipid carriers of fenofibrate with enhanced oral bioavailability and efficacy.
Pyo YC; Tran P; Kim DH; Park JS
Colloids Surf B Biointerfaces; 2020 Dec; 196():111331. PubMed ID: 32906001
[TBL] [Abstract][Full Text] [Related]
7. Preparation of Ergosterol-Loaded Nanostructured Lipid Carriers for Enhancing Oral Bioavailability and Antidiabetic Nephropathy Effects.
Dong Z; Iqbal S; Zhao Z
AAPS PharmSciTech; 2020 Jan; 21(2):64. PubMed ID: 31932990
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of S(+)-zaltoprofen oral bioavailability using nanostructured lipid carrier system.
Pham TMA; Lee DH; Na YG; Jin M; Jung M; Kim HE; Yoo H; Won JH; Lee JY; Baek JS; Han SC; Lee HK; Cho CW
Arch Pharm Res; 2022 Nov; 45(11):822-835. PubMed ID: 36307644
[TBL] [Abstract][Full Text] [Related]
9. Design, characterization and in vivo evaluation of nanostructured lipid carriers (NLC) as a new drug delivery system for hydrochlorothiazide oral administration in pediatric therapy.
Cirri M; Maestrini L; Maestrelli F; Mennini N; Mura P; Ghelardini C; Di Cesare Mannelli L
Drug Deliv; 2018 Nov; 25(1):1910-1921. PubMed ID: 30451015
[TBL] [Abstract][Full Text] [Related]
10. Formulation, Characterization, and Pharmacokinetic Studies of 6-Gingerol-Loaded Nanostructured Lipid Carriers.
Wei Q; Yang Q; Wang Q; Sun C; Zhu Y; Niu Y; Yu J; Xu X
AAPS PharmSciTech; 2018 Nov; 19(8):3661-3669. PubMed ID: 30324361
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Study of Atorvastatin Nanostructured Lipid Carriers through Multivariate Conceptualization and Optimization.
Ghanem HA; Nasr AM; Hassan TH; Elkhoudary MM; Alshaman R; Alattar A; Gad S
Pharmaceutics; 2021 Jan; 13(2):. PubMed ID: 33525642
[TBL] [Abstract][Full Text] [Related]
12. Size-exclusive effect of nanostructured lipid carriers on oral drug delivery.
Li H; Chen M; Su Z; Sun M; Ping Q
Int J Pharm; 2016 Sep; 511(1):524-537. PubMed ID: 27452421
[TBL] [Abstract][Full Text] [Related]
13. Nanostructured lipid carriers used for oral delivery of oridonin: an effect of ligand modification on absorption.
Zhou X; Zhang X; Ye Y; Zhang T; Wang H; Ma Z; Wu B
Int J Pharm; 2015 Feb; 479(2):391-8. PubMed ID: 25556104
[TBL] [Abstract][Full Text] [Related]
14. Lipid-based nano-formulation platform for eplerenone oral delivery as a potential treatment of chronic central serous chorioretinopathy:
Abd-Elhakeem E; El-Nabarawi M; Shamma R
Drug Deliv; 2021 Dec; 28(1):642-654. PubMed ID: 33787445
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Oral Absorption of Amisulpride Via a Nanostructured Lipid Carrier-Based Capsules: Development, Optimization Applying the Desirability Function Approach and In Vivo Pharmacokinetic Study.
El Assasy AEI; Younes NF; Makhlouf AIA
AAPS PharmSciTech; 2019 Jan; 20(2):82. PubMed ID: 30652198
[TBL] [Abstract][Full Text] [Related]
16. Quality by design (QbD)-based fabrication of atazanavir-loaded nanostructured lipid carriers for lymph targeting: bioavailability enhancement using chylomicron flow block model and toxicity studies.
Gurumukhi VC; Bari SB
Drug Deliv Transl Res; 2022 May; 12(5):1230-1252. PubMed ID: 34110597
[TBL] [Abstract][Full Text] [Related]
17. Preparation and characterization of nimodipine-loaded nanostructured lipid systems for enhanced solubility and bioavailability.
Teng Z; Yu M; Ding Y; Zhang H; Shen Y; Jiang M; Liu P; Opoku-Damoah Y; Webster TJ; Zhou J
Int J Nanomedicine; 2019; 14():119-133. PubMed ID: 30613141
[TBL] [Abstract][Full Text] [Related]
18. Enhanced oral bioavailability of nintedanib esylate with nanostructured lipid carriers by lymphatic targeting: In vitro, cell line and in vivo evaluation.
Patel P; Patel M
Eur J Pharm Sci; 2021 Apr; 159():105715. PubMed ID: 33453388
[TBL] [Abstract][Full Text] [Related]
19. Nose to Brain Delivery of Astaxanthin-Loaded Nanostructured Lipid Carriers in Rat Model of Alzheimer's Disease: Preparation, in vitro and in vivo Evaluation.
Shehata MK; Ismail AA; Kamel MA
Int J Nanomedicine; 2023; 18():1631-1658. PubMed ID: 37020692
[TBL] [Abstract][Full Text] [Related]
20. Nanostructured Lipid Carriers Loaded with Baicalin: An Efficient Carrier for Enhanced Antidiabetic Effects.
Shi F; Wei Z; Zhao Y; Xu X
Pharmacogn Mag; 2016; 12(47):198-202. PubMed ID: 27601850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
